AbbVie ABBV Epkinly — Net revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by AbbVie in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: AbbVie’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbbVie's epkinly — net revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbbVie's epkinly — net revenues?
- AbbVie (ABBV) reported epkinly — net revenues of $83M in Q1 2026.
- How has AbbVie's epkinly — net revenues changed year-over-year?
- AbbVie's epkinly — net revenues increased by 62.7% year-over-year, from $51M to $83M.
- What is the long-term trend for AbbVie's epkinly — net revenues?
- Over 2 years (2023 to 2025), AbbVie's epkinly — net revenues has grown at a 195.7% compound annual growth rate (CAGR), from $31M to $271M.
- What does epkinly — net revenues mean?
- This metric represents the total net sales generated from the commercialization of a specific oncology therapeutic product. It reflects the gross revenue adjusted for rebates, discounts, and returns associated with the product's market distribution. As a key growth driver in the company's hematology-oncology portfolio, it indicates the market adoption and clinical penetration of this specific bispecific antibody therapy.